Fri-24-05-2019, 20:34 PM
This study looked at circulating plasma claudin‐3 in patients with psoriasis
Source: onlinelibrary.wiley.com
*Early view funding unknown.
Quote:
Background:
Gut dysbiosis and increased intestinal permeability play a significant role in the pathogenesis of psoriasis and its comorbidities. Claudin‐3 is a key component of tight junctions, which may serve as marker of gut barrier integrity.
Objectives:
The aim of the study was to investigate circulating plasma claudin‐3 in patients with psoriasis and to evaluate clinical and metabolic factors, which determine its concentration.
Methods:
This cross‐sectional study included 60 patients with psoriasis (39 men and 21 women, mean age: 45.6±12.1 years) and 30 healthy controls (18 men and 12 women, mean age: 46.3±15.5 years) age, sex and body mass index‐matched. Plasma claudin‐3 concentration was measured using an enzyme‐linked immunosorbent assay.
Results:
Plasma claudin‐3 concentration was significantly higher in patients with psoriasis in comparison to healthy control [median (interquartile range), 50.7 ng/ml (47.3‐54.2) vs 43.3 ng/ml (42.3‐44.2), p < 0.001]. Patients who achieved ⊗PASI90 response after 16 weeks of treatment showed tendency to decrease in circulating claudin‐3 plasma concentration. Positive correlations between claudin‐3 concentration and the PASI score (r = 0.828; p < 0.001) as well as claudin‐3 and neutrophil‐to‐lymphocyte ratio (r = 0.847; p < 0.001) were found. A multivariable linear regression analysis confirmed association of claudin‐3 with the PASI score (p < 0.001), neutrophil‐to‐lymphocyte ratio (p < 0.01) and active smoking (p < 0.05).
Conclusion:
Claudin‐3, a biomarker for gut permeability, is increased in psoriasis and correlates with disease severity and smoking. Further investigations are needed to determine whether reinforcing intestinal barrier may be a new therapeutic target in psoriasis.
Source: onlinelibrary.wiley.com
*Early view funding unknown.